Show simple item record

dc.contributor.authorÇetinkaya, Serap
dc.contributor.authorÖzbilüm Şahin, Nil
dc.contributor.authorYenidünya, Ali Fazıl
dc.contributor.authorTüzün, Burak
dc.date.accessioned2024-03-04T07:37:39Z
dc.date.available2024-03-04T07:37:39Z
dc.date.issued2023tr
dc.identifier.urihttps://hdl.handle.net/20.500.12418/14550
dc.description.abstractCOVID-19 pandemic emerged in December 2019, and it is still a global threat with quite a few variants. The B.1.1.529, Omicron, identified in South Africa in 2021, was one of the most notorious variants due to its high infection and mutability capacity. The Omicron variant had mutations in the S region of the key RBD which boosted the transmission ability of the virus. Resistance to antibodies and vaccines has been the key features of this variant. The rise of antibody-evading variants has reached alarming proportions and discovery of small molecule inhibitors has been thought to be a solution to this problem. Presently scientific attention has been substantially directed towards computational drug design performing molecular simulations to generate effective chemical agents to tackle the Omicron variant.tr
dc.language.isoengtr
dc.publisherNovatr
dc.rightsinfo:eu-repo/semantics/openAccesstr
dc.subjectCOVID-19tr
dc.subjectomicrontr
dc.subjectSARS-CoV-2tr
dc.subjectspike proteintr
dc.subjectvaccinetr
dc.subjectmolecular dockingtr
dc.titleOmicron: Emergence, Detection, and Responsetr
dc.typebookParttr
dc.relation.journalAdvances in Health and Diseasetr
dc.contributor.departmentFen Fakültesitr
dc.contributor.authorIDhttps://orcid.org/0000-0002-9886-977Xtr
dc.identifier.endpage183tr
dc.identifier.startpage161tr
dc.relation.publicationcategoryUluslararası Kitapta Bölümtr


Files in this item

This item appears in the following Collection(s)

Show simple item record